CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ARCAGY/ GINECO GROUP
• Treatments: Cisplatin; Irinotecan

Criteria

Inclusion Criteria:

• Histologically proven primitive epidermoid or andenocarcinoma Cervix

• FIGO stage IIB (obviously parameter attack), III or IVA

• No previous chemotherapy nor radiotherapy

• Patient for whom a radiochemotherapy is envisaged as first intention treatmentof her cervix carcinoma

• PS ECOG < 2

• Life expectancy > 12 weeks

• Written consent given

Exclusion Criteria:

• Other malignant cervix tumor histology

• Visceral remotly metastasis

• Other malignant tumor since 5 years, except spino or baso-cellular treaten and cured cancer

• Anormal labs values

• Peripheric neuropathy CTC > 2

• Auditory loss > 2

• Cardiopathy

• Inflammatory digestive pathology

• Evolutive infection

• Other experimental concommitant treatment

• Lacting or pregnant women